OPM obtains development grants from the Bourgogne Franche-Comté region

OPM obtains development grants from the Bourgogne Franche-Comté region

Dijon, France, October 14, 2025, at 6:00 pm CEST – Oncodesign Precision Medicine (OPM) (ISIN: FR001400CM63; Mnemonic: ALOPM), a biopharmaceutical company specializing in precision medicine for the treatment of resistant and metastatic cancers, announces that it has received notification of the allocation of an investment grant from the Bourgogne Franche-Comté Region.